Search

New phase 3 data presented at the annual Congress of the European Academy of Dermatology and Venereology supports the use of nemolizumab as a potential new treatment for prurigo nodularis. The OLYMPIA 1 study showed significant improvements in itch and skin lesions after 16 weeks of treatment with nemolizumab compared to placebo. Another study, OLYMPIA 2, also demonstrated positive results. Nemolizumab is a first-in-class interleukin-31 receptor alpha antagonist that may provide a new option for patients with this chronic neuroimmune skin condition. Additionally, a separate study presented data on the JAK inhibitor abrocitinib as a potential treatment for prurigo nodularis and chronic pruritus of unknown origin (CPUO). Both studies showed promising results and may offer new therapeutic options for these difficult-to-treat conditions. [Extracted from the article]

Nemolizumab, an inhibitor of interleukin-31 (IL-31), has shown continued efficacy and safety for prurigo nodularis in a 52-week open-label follow-up trial. The drug has been well-tolerated and has not been associated with any new adverse events. Current treatment options for prurigo nodularis are not effective for most patients, making nemolizumab a potentially important advancement in the field. Additionally, nemolizumab has shown long-term efficacy against itch in patients with atopic dermatitis. The drug is currently under review by regulatory agencies for the treatment of both prurigo nodularis and atopic dermatitis. [Extracted from the article]

The article discusses the diagnosis and treatment of prurigo nodularis, a severe skin disease characterized by highly itchy nodules. The author emphasizes the importance of recognizing the differences in presentation across different skin types, particularly in patients with darker skin. Patients with darker skin types may have larger nodules that can vary in shape, making diagnosis more challenging. The article also highlights research suggesting that prurigo nodularis may have a more up-regulated inflammatory profile in Black patients, which could impact treatment options. The author recommends that clinicians stay current with the growing array of treatment options and consider prurigo nodularis in Black patients to accelerate diagnosis and reduce disparities in care. [Extracted from the article]

The Food and Drug Administration (FDA) has approved nemolizumab, a monoclonal antibody, for the treatment of prurigo nodularis (PN), a rare skin condition. Nemolizumab, marketed as Nemluvio, inhibits interleukin (IL)-31 signaling and will be available as a prefilled pen for subcutaneous injection. The approval is based on data from the phase 3 OLYMPIA clinical trial program, which showed significant reduction in itch intensity and improvement in skin lesions in patients treated with nemolizumab compared to placebo. Nemolizumab is also under FDA review for treating atopic dermatitis. [Extracted from the article]

A recent international cohort study found that patients with prurigo nodularis (PN) have a higher risk of cardiovascular diseases and mortality, particularly among women and White patients. The study analyzed electronic health records of 64,801 patients with PN and matched them with individuals without PN. The results showed that patients with PN had a higher risk of death and major adverse cardiovascular events, as well as heart failure, thrombotic venous disease, angina pectoris, and peripheral arterial diseases. However, the increased risk was only observed in White patients and not in people of color. The study suggests that healthcare providers should consider the potential risk of cardiovascular disease in the care of patients with PN. [Extracted from the article]

Galderma has announced that the FDA has accepted its Biologics License Application for nemolizumab, a monoclonal antibody, for the treatment of prurigo nodularis and moderate to severe atopic dermatitis in adolescents and adults. Nemolizumab has also been granted FDA Priority Review for prurigo nodularis. The European Medicines Agency has accepted Galderma's Marketing Authorization Applications for both indications as well. These regulatory developments are based on data from the phase III OLYMPIA clinical trial program, which showed significant improvements in itch intensity and skin lesions in patients treated with nemolizumab compared to placebo. [Extracted from the article]

Galderma has announced that the FDA has accepted its Biologics License Application for nemolizumab, a monoclonal antibody, for the treatment of prurigo nodularis and moderate to severe atopic dermatitis in adolescents and adults. The drug has also been granted FDA Priority Review for prurigo nodularis. The European Medicines Agency has accepted Galderma's Marketing Authorization Applications for both indications as well. These regulatory developments are based on data from the phase III OLYMPIA clinical trial program, which showed significant improvements in itch intensity and skin lesions in patients treated with nemolizumab compared to placebo. [Extracted from the article]

The article focuses on the benefits of dupilumab for prurigo nodularis (PN). It highlighting two phase 3 trials that demonstrated statistically significant improvements in itch and skin lesions in patients receiving dupilumab compared to those receiving a placebo. The results of these trials led to the Food & Drug Administration (FDA) approval of dupilumab as the first treatment for PN in the United States.